Merck Touts Melanoma Phase 1 Results and 2 Other Hot Stocks to Watch
Merck & Co. (NYSE:MRK): Current price $48.59
Merck was quite impressive in its presentation to the American Society of Clinical Oncology over the weekend, and its shares are reflecting it on Monday, big time. The results from its Phase 1 study of a treatment for advanced melanoma, are being compared by analysts to recent announcements from Bristol-Myers Squibb Co. (NYSE:BMY), which predicted “the beginning of the end of cancer” while unveiling test results for its melanoma treatment Yervoy in May. Meanwhile, Merck shares are up more than 5.5 percent in late morning trading.
Sprint Nextel Corporation (NYSE:S): Current price $7.22
On Monday, Sprint announced its plans to work jointly with United Cerebral Palsy so as to raise awareness for Sprint’s speech-to-speech services, and to increase their usage among individuals suffering from cerebral palsy. The partners will jointly advocate products and services of SprintRelay while advancing UCP’s efforts to promote the accessibility for people by means of a wide spectrum of disabilities. Sprint offers an array of unique devices and services permitting persons with hearing and speech disabilities to communicate with others, enhancing their ability to live independently.
General Electric Company (NYSE:GE): Current price $23.55
GE has attained a resolution with the New York Attorney General’s office, concluding an inquiry into a GE health-care credit card which charged interest rates up to 27 percent. The settlement with GE Capital Retail Bank and CareCredit affords protections for consumers who were typically unaware of the costs, according to Attorney General Eric Schneiderman, who commented in a statement that “this agreement will help New Yorkers by stopping providers from charging large, upfront fees for future services and from glossing over the huge interest rates associated with CareCredit.”